The nation’s medical device industry is expected to grow as much as 8.5 percent this year to a record high, supported by demand for medicare devices from a steadily aging population worldwide, the Industrial Economics and Knowledge Center (IEK) said.
If that proves the case, it would be the industry’s fifth consecutive year of revenue growth of more than 5 percent, according to the research house’s latest projection.
The growth comes against a decline of Taiwan’s manufacturing sector, which is expected to shrink by 1.71 percent year-on-year to NT$17.44 trillion (US$546.26 billion) this year, as demand for Taiwanese electronic goods weakens amid the flagging global economy.
“The medical device industry is less affected by macroeconomic ups-and-downs. ‘Brexit’ should not have any significant impact on the industry,” center analyst Tsai Meng-nan (蔡孟男) told a news conference on Monday last week. “Rather, it is more prone to regulatory changes.”
Taiwan’s medical device industry is expected to expand at an annual rate of between 6.9 percent and 8.5 percent this year to between NT$100.81 billion and NT$102.32 billion in revenue, from last year’s NT$94.3 billion, Tsai said.
Tai attributed the growth to rising medical spending as the world’s population ages. Spending in the US and Germany, in particular, accelerated last year — increasing at an annual rate of 4.7 percent and 4 percent respectively, from a compound annual growth rate of less than 4 percent for the two countries between 2011 and 2014, the center said.
“We believe the nation’s medical device industry is heading to an up cycle this year and the industry has promising business prospects,” Tsai said.
Contact lenses and blood sugar testing strips are the two largest revenue contributors, constituting 24 percent and 14 percent respectively of the local industry’s total shipments this month, the center said.
US, Japan and China are the top three export destinations for the industry, the center said.
In the first half this year, major Taiwanese firms such as medical bloodlines and tubing systems supplier Bioteque Corp (邦特生物科技) and contact lens supplier St Shine Optical Co (精華光學) saw their revenues increase 5.3 percent annually, the center said.
St Shine, the nation’s biggest eye contact lens maker, which sells primarily to Japanese clients such as SEED Co, is expected to outperform its local peers.
The company is expected to increase revenue by 12.59 percent to NT$6.6 billion this year, from NT$5.86 billion last year, Credit Suisse analyst Jeremy Chen (陳建名) said.
For the last quarter, St Shine is expected to report a 12 percent increase in net profit to NT$459 million, or NT$9.1 per share, Chen said.
St Shine reported NT$408.67 million in net profit in the first quarter of this year.
Chen expects the company’s gross margin last quarter to increase to 43.5 percent from 41.9 percent in the previous quarter.
Gogoro Inc (睿能創意) yesterday launched its first electric bicycle, the Gogoro Eeyo 1, in Taiwan, after unveiling the bike in New York in late May and in France on Tuesday. The company said it would also introduce the series in other European countries such as Germany and the Netherlands. The “Eeyo project” is the fourth of Gogoro’s eight projects that concentrate on smart transportation, which includes Gogoro’s electric scooter, battery swap system and electric scooter sharing service, company founder and chief executive officer Horace Luke (陸學森) told a media briefing in Taipei. “There are various types of city commuters. We will not
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price
NOT A PANACEA: Offering 5G services would not solve the problem of declining telecom incomes, chairman Sheih Chi-mau said, expecting a flat 5G telecom revenue Chunghwa Telecom Co (中華電信) yesterday became the nation’s first telecom to debut its 5G services, offering tiered tariffs that include a threshold of NT$599 and flat rates, as it aims to switch half of its subscribers to the 5G network within three years. Subscribers would have unlimited data transmission for monthly fees starting at NT$1,399 — the same flat rate as when the company launched its 4G service in 2014 — and they can subscribe to the highest-rate plan for NT$2,699 per month for faster data transmission speeds and larger bandwidth, the company said. Data transmission speeds would be within the range
ROW: A probe would determine if the rights of shareholders who were not allowed to vote yesterday had been violated, while the stock exchange also wants answers The election of board directors yesterday at Tatung Co (大同) sparked controversy after the company blocked some institutional and individual shareholders from participating in the general shareholders’ meeting, prompting the Financial Supervisory Commission (FSC) to announce that the vote would be investigated. Lin Kuo Wen-yen (林郭文艷) was re-elected as chairwoman of the household-appliance maker’s nine-member board, but prior to the vote she announced that several shareholders would not have voting rights. They were being denied a vote because they had contravened the Business Mergers and Acquisitions Act (企業併購法), and the Act Governing Relations Between the People of the Taiwan Area and